about
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaquesA virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionZika viral dynamics and shedding in rhesus and cynomolgus macaquesA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelEvaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque modelZika virus protection by a single low-dose nucleoside-modified mRNA vaccinationLong-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccineZika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus MonkeysA DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primatesResponse of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsHigh dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity modelRapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.Pattern of SIVagm infection in patas monkeys suggests that host adaptation to simian immunodeficiency virus infection may result in resistance to infection and virus extinction.Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques.Rapid development of a DNA vaccine for Zika virusRhesus macaque lymph node PD-1(hi)CD4+ T cells express high levels of CXCR5 and IL-21 and display a CCR7(lo)ICOS+Bcl6+ T-follicular helper (Tfh) cell phenotype.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesType I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.Suppression of transforming growth factor β receptor 2 and Smad5 is associated with high levels of microRNA miR-155 in the oral mucosa during chronic simian immunodeficiency virus infection.Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.SIV Infection of Lung MacrophagesMucosal and peripheral Lin- HLA-DR+ CD11c/123- CD13+ CD14- mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection.Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in MacaquesImmunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response.Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodiesRapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys.Effect of chronic morphine administration on circulating dendritic cells in SIV-infected rhesus macaques.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaquesInvestigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.
P50
Q24630281-BCDFF32B-4C64-49D7-A3FF-5B766C79203DQ24631774-8BC597D0-A3FB-42E7-8030-0618B92A4B37Q27087751-D22DFF9A-606A-4431-89FC-D0D9EB7A6A6AQ27344720-C7E309FA-9BDD-40F9-94CF-B18DB8975490Q28544990-D7C01D8B-DC36-42B8-B648-E6C1B1D6E2F8Q28656365-BAE01402-FEED-41E8-9203-6AC10614A7FCQ28743435-31837405-9BFA-428E-BB52-FBD6E804B478Q29587262-B94A7CFE-705B-4778-AD91-0D4CA4DB3076Q30398956-9880938D-70DE-4A29-A6F2-B273D77E0A22Q30494064-4A4F366D-6F3E-4AEC-A311-508E5C42F80BQ33268303-4CAFB280-D1EC-4D85-9830-25590A49CC88Q33597744-130AB94B-6299-4FC7-A020-5DC3EF73B1CEQ33737723-315A2D96-1D14-48EC-96DA-8486D620FF24Q33987553-E3639668-25D6-4368-AF58-4F0F7280A308Q34020988-90873067-32D0-4B97-B135-E564369AFC2BQ34181830-9BDEF2C9-452A-4BEE-8F08-5543CF9BE5F1Q34377004-3A93CF85-BA41-481D-A374-B7E18583CFC1Q34542032-89B401B0-9287-4908-9A9A-C02F11284B56Q34635510-D462B391-6734-4474-90A6-0EAD3329C549Q34637968-8C5BDD6A-E1F3-4046-94C3-1C4BFDB88873Q34791232-585024CE-F3E0-438E-9DED-769A86CF1826Q35018048-B2A291A7-3C7D-4DA8-9CA2-E4869D659C31Q35076724-5E18E081-DA89-4D56-BA15-0E192ED45A8AQ35216862-59095A7E-DBAA-486C-819F-4077DB8353CAQ35413374-A9478A57-2D23-4C8D-B431-DBD65374E0EFQ35560751-AE130E82-8591-494F-9559-72C632D34145Q35665916-3F8657C9-0103-46DF-A103-AF3ABB6401EFQ35849596-0C45F521-0429-4500-8766-C98E70502742Q35861190-D3BFF339-80B8-4E24-A175-3792A356598BQ35974961-D4E5F1FD-3B4D-4FA9-9989-BA01DCB7AEF9Q36017750-485106A5-DEE9-4BF3-AC90-B8EF5E30C7A2Q36276936-D9078E2D-DB4B-4034-972C-070E0753D52EQ36300153-059EC1C9-61B6-47EA-81FB-829137286A76Q36379235-A4DDCBB1-420B-435B-9FB6-BF580235E6DEQ36525047-7142BF5F-245D-4DB9-B86C-38C9125E8CDCQ36828434-8B334015-E194-440B-85CC-B8A180426F62Q36945772-8589B667-E07D-4D67-A4E1-06E7697D5C24Q37021717-14F665B8-9564-48C0-ABBB-CFB0602B475FQ37109010-6CD9063E-F73C-4318-A311-F43D0F803986Q37157152-8B173D65-F92F-426E-89D4-1BA788802FFD
P50
name
Mark G Lewis
@ast
Mark G Lewis
@en
Mark G Lewis
@nl
type
label
Mark G Lewis
@ast
Mark G Lewis
@en
Mark G Lewis
@nl
prefLabel
Mark G Lewis
@ast
Mark G Lewis
@en
Mark G Lewis
@nl